Freedom of Information Request: 0326 2019/20
Question 1a
Does your trust treat advanced breast cancer ?
Question 1b
If none, where are your patients referred?
Question 2
In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
| HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive] | |
| HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative] | |
| HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive] | |
| HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] – Triple negative disease | |
| Not Known |
Question 3
In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
Please see attached document
